Sign in

    Aman Witch

    Vice President and Equity Analyst at Astute Investment Management

    Aman Witch is a Vice President and Equity Analyst at Astute Investment Management, specializing in financial sector research with dedicated coverage of major firms such as JPMorgan Chase, Bank of America, and Citigroup. Recognized for insightful fundamental analysis, Aman has achieved a consistent success rate of approximately 65% on published recommendations, generating double-digit annualized returns for clients and earning an above-average ranking among peers on leading analyst tracking platforms. Beginning his career in 2014 as a Research Associate at PineBridge Investments, Aman advanced to Astute Investment Management in 2019, where his deep sector expertise and rigorous approach have driven strong portfolio performance. Holding FINRA Series 7 and 63 licenses, Aman is known for his analytic rigor and effective communication with institutional clients.

    Aman Witch's questions to DR REDDYS LABORATORIES (RDY) leadership

    Aman Witch's questions to DR REDDYS LABORATORIES (RDY) leadership • Q1 2026

    Question

    Aman Witch of Astute Investment Management questioned the competitiveness of Dr. Reddy's semaglutide API, the potential impact of an adverse court ruling in India on the Canada launch, and the flexibility to scale up manufacturing capacity.

    Answer

    CEO Erez Israeli expressed confidence that their scaled-up API will be cost-competitive with others, including those from China. He acknowledged that an adverse ruling in the Delhi High Court is primarily a risk for the Canadian launch timeline, not just the Indian one. He stated that while there is some upside to the guided 10-12 million pen capacity, doubling it in calendar '26 would not be possible.

    Ask Fintool Equity Research AI